SCHEMBL6092688

SCHEMBL6092688

CCCN1C(=O)C(=Cc2ccc(-c3ccc(Cl)c([N+](=O)[O-])c3)o2)SC1=S

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP3K5 Q99683 6/20 0.59
▸ HIF1AN Q9NWT6 1/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ MCL1 Q07820 3/20 0.55
▸ MAPT P10636 3/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ POLB P06746 2/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ EIF4E P06730 1/20 0.55
▸ EIF4G1 Q04637 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ RECQL P46063 1/20 0.55
▸ DUSP3 P51452 1/20 0.54
▸ PKM P14618 2/20 0.53
▸ PTPN7 P35236 1/20 0.53
▸ PTPN12 Q05209 1/20 0.53
▸ PTPN22 Q9Y2R2 1/20 0.53
▸ STAT3 P40763 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6092684 1.00 MAP3K5 (0.59) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3894146 0.94 STAT3 (0.60) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3894155 0.94 STAT3 (0.60) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3907019 0.89 POLB (0.61) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3907023 0.89 POLB (0.61) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3895622 0.88 MEN1 (0.65) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3895615 0.88 MEN1 (0.65) MAP3K5HIF1ANMEN1KMT2AMCL1
SCHEMBL3897122 0.88 MAPT (0.69) MAP3K5MEN1KMT2AMCL1MAPT
SCHEMBL3897115 0.88 MAPT (0.69) MAP3K5MEN1KMT2AMCL1MAPT
SCHEMBL15374270 0.82 HIF1AN (0.77) MAP3K5HIF1ANMEN1KMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MAP3K5 1092/4885HIF1AN 647/4885MEN1 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback